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The bacterial capsule is a recognized virulence factor in pathogenic bacteria. It likely works as an anti-
phagocytic barrier by minimizing complement deposition on the bacterial surface. With the continual 
rise of bacterial pathogens resistant to multiple antibiotics, there is an increasing need for novel drugs.  
In the Wzy-dependent pathway, the biosynthesis of capsular polysaccharide (CPS) is regulated by a 
phosphoregulatory system, whose main components consist of bacterial-tyrosine kinases (BY-kinases) 
and their cognate phosphatases. The ability to regulate capsule biosynthesis has been shown to be vital 
for pathogenicity, because different stages of infection require a shift in capsule thickness, making the 
phosphoregulatory proteins suitable as drug targets. Here, we review the role of regulatory proteins 
focusing on Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli and discuss their 




antibiotic resistance, bacterial pathogens, capsule, drug discovery, protein tyrosine kinase, protein 
tyrosine phosphatase, Wzy.
Introduction 
The continual rise of multiply antibiotic resistant bacterial pathogens is resulting in infections which 
are almost untreatable. The further lack of novel anti-microbials in the drug development pipeline may 
result in us retreating to a pre-antibiotic era [1]. Thus, the search for novel targets for anti-infectious 
agents is of utmost importance.  
Polysaccharide capsules are critical determinants for the ability of a wide range of bacterial 
pathogens to cause invasive disease. They form the outermost layer of the cells, and are thought vital 
due to their ability to act as an anti-phagocytic factor. Our work focuses on understanding the 
mechanisms behind the biosynthesis of Wzy-dependent capsules, with a focus on the major human 
pathogen Streptococcus pneumoniae. However, other pathogens also possess Wzy-dependent capsules 
important for their virulence, including Staphylococcus aureus, Escherichia coli and Klebsiella 
pneumoniae. 
The capsule of S. pneumoniae has been used as a relatively successful target for the 
development of vaccines, resulting in significant decreases in carriage and invasive disease. However, 
to date no drugs have been developed that target the biosynthesis and regulation of this crucially 
important virulence factor, even though unencapsulated bacteria are essentially avirulent.  
The intent of this review is to provide an outline of how the mechanisms governing capsule 
synthesis and regulation can be approached as drug targets, as applied to major human pathogens. We 
will discuss the importance to virulence of the capsule, as well as the mechanisms involved in its 
synthesis and regulation, with a particular focus on S. pneumoniae. Finally, we will discuss some 
proteins which we feel could be targeted in an effort to produce novel antimicrobials to help us in the 
continuing fight against infectious disease. 
 
 
Capsule as a virulence factor 
Polysaccharide capsules are produced by an array of both Gram-positive and -negative bacteria, for all 
of whom they are important for virulence. In recent times, much work has been completed on 
furthering our understanding of the mechanisms involved in the contribution it makes to pathogenicity. 
We are focused on the synthesis and regulation of the capsule in S. pneumoniae, as for this pathogen it 
is widely recognised as its major virulence factor. 
 
S. pneumoniae 
Pneumonia is the single biggest killer of children under the age of five. As the major causative agent, S. 
pneumoniae alone accounts for 700,000 to 1 million deaths annually among children aged 1-59 months 
[2,3]. This includes deaths mainly due to pneumonia, meningitis, and febrile bacteremia, but not the 
compounding effects of co-infection with HIV. According to the World Health Organisation (WHO), 
the biggest disease burden is in the WHO African Region and WHO South-East Asia Region. With the 
majority of cases occurring in developing countries lacking proper estimates, however, the true scope 
of disease burden is unknown. In 2000 alone, 14.5 million cases of serious pneumococcal infection is 
estimated to have occurred in children aged 1-59 months, resulting in approximately 826,000 deaths [4]. 
As can be expected, HIV and other immune deficiencies greatly increase the risk of contracting 
pneumococcal disease, consequently mortality among HIV positive individuals is substantially higher.  
 Among conditions with a high morbidity but lower mortality, S. pneumoniae is the most 
common cause of otitis media, making it the single largest reason for prescribing antibiotic treatment 
[5]. This makes it responsible for massive impacts on health budgets in developed nations, with 
estimates in the US alone > 2 billion USD annually.  
The pathogenesis of S. pneumoniae begins with asymptomatic colonisation of the 
nasopharynx, its natural reservoir responsible for the spread of the bacteria from person to person. The 
pathogen can then undergo a switch to invasive disease, resulting in upper or lower respiratory tract 
infections; give the bacteria the opportunity to cross over into the blood stream; or even cross the 
blood-brain barrier, with pneumonia, bacteremia, and meningitis, respectively, as possible outcomes. 
Furthermore, the increasing development of multi-antibiotic resistant strains and the inefficiencies 
associated with the current vaccines, means that the need for new treatments is vital. Traditional 
problems with compliance with antibiotic treatment regimens [6,7] have inevitably been a 
compounding factor in the rise of penicillin resistant S. pneumoniae. Treatment is further complicated 
by the fact that penicillin resistant strains tend to be multi-drug resistant as well. Many virulence 
factors are implicated in the ability of the pathogen to cause disease, and these have been reviewed 
recently [8]. However, the capsule is widely recognized as the one critical factor and as such has been a 
major focus of research into the understanding of this pathogen. 
The polysaccharide capsule is the serotype-determining factor, and all but two of the 93 
serotypes of S. pneumoniae found to date have the capsule synthesised by a Wzy-dependent 
mechanism [9]. Thus, this represents a promising target for drug development. The capsule is the target 
of the currently used vaccines. However, these provide serotype-specific protection, and as such 
protection is limited. Indeed, the very successful heptavalent pneumococcal conjugate vaccine (PCV7) 
targets only 7 serotypes. While it has provided protection in many populations since its introduction, 
and a recently introduced 13-valent vaccine shows promise, continual studies are illustrating that 
serotype replacement is occurring, resulting in a rise in the carriage prevalence of uncovered serotypes 
[10].  
The importance of the capsule is evident in a number of different ways. All clinical isolates of 
S. pneumoniae causing invasive disease are encapsulated. Indeed, unencapsulated bacteria have only 
been associated with superficial infections such as conjunctivitis, and the capsule has been shown to 
enhance such infections [11]. Numerous studies have shown significant correlations of serotype with 
nasopharyngeal carriage prevalence, invasiveness, disease incidence, and even risk of death due to 
pneumococcal pneumonia [12]. This need for capsule has also been illustrated in numerous 
pneumococcal animal models of infection. One of the earliest studies by MacLeod & Krauss [13] 
showed the importance of capsule by correlating virulence in mice with the levels of capsule produced 
by different strains in vitro. In more recent times, defined mutations have produced similar results. 
Morona et al. [14,15] used defined mutations in various capsule regulatory genes (discussed below), 
which leads to various defects in the ability to produce capsule, and these strains all showed significant 
defects in the ability to colonise and cause invasive disease. The importance of capsule to 
asymptomatic colonisation has also been illustrated using defined mutations in multiple strain 
backgrounds [16,17].  
Thus, while the importance of the capsule to pneumococcal virulence is unquestioned, the 
obvious question is what precise role does it play? This role has long been postulated to involve its 
ability to act as an anti-phagocytic barrier. However, until recently there have been few studies 
investigating the exact mechanisms behind this. A recent study by Hyams et al. [18] examined this in 
more detail. The complement system is recognised as a crucial component of the host’s ability to fight 
off infection by the pneumococcus, with neutrophil opsonophagocytosis of S. pneumoniae known to be 
largely dependent on complement [19,20]. Using defined unencapsulated mutants in multiple strain 
backgrounds, the authors illustrated the capsule is able to inhibit the classical complement pathway by 
preventing binding of both IgG and C-reactive protein, as well as reducing the activation of the 
alternative complement pathway [18]. Unencapsulated bacteria were more heavily opsonised by 
C3b/iC3b, as had been seen previously [21,22], which resulted in increased phagocytosis by 
neutrophils. Even in the absence of complement and antibody, unencapsulated bacteria were 
phagocytosed to a higher degree and killed. Thus, this clearly illustrated that the capsule employs 
multiple mechanisms to protect the pneumococcus from phagocytosis. 
While numerous virulence factors undoubtedly contribute to the pathogen’s ability to resist 
complement deposition and phagocytosis [23–25], two recent studies have illustrated the central 
dominance of the capsule in this strategy [24,26]. Both of these studies showed the fundamental 
importance of capsule by leaving the genetic background the same and only changing the capsule type. 
Using these strains they showed capsule serotype changes resulted in marked differences in C3 
deposition, neutrophil phagocytosis and infection using in vivo models. These data correlate closely 
with the knowledge that capsule types differ in their epidemiological properties. Interestingly, these 
differences were unrelated to any significant difference in capsule thickness between the strains [27].  
Additional recent studies have investigated the size and structure of the capsular 
polysaccharides of S. pneumoniae as a critical feature, testing if thicker capsule is more advantageous 
for infection [13]. Weinberger et al. [28] showed a correlation between the thickness of capsule, 
increased resistance to in vitro killing by neutrophils, and increased prevalence in nasopharyngeal 
colonisation in the community. Interestingly, they further identified a link between the more prevalent 
serotypes and their polysaccharide structure, suggesting that serotypes that produce less metabolically 
costly polysaccharides produce thicker capsules, and are thus more prevalent. A recent study has 
implicated another reason for the selection of particular serotypes. Lysenko et al. [29] used 
mathematical modelling as well as in vivo animal models to suggest the intraspecies competition, such 
as between S. pneumoniae and H. influenzae in the nasopharynx, will lead to the selection of particular 
capsular serotypes within the host. 
However, the story of capsule is not all that simple. Indeed, while the capsule is critical for the 
ability of cells to cause disease, it also hinders the ability of the pathogen to attach to host epithelial 
cells [30,31], likely due to its ability to shield adherence factors [32]. The capsule has also been shown 
to inhibit the formation of biofilms of S. pneumoniae in vitro [33]. Additionally, the pneumococcus is 
known to undergo spontaneous phase variation between two phenotypes, opaque and transparent [34]. 
While the exact mechanism behind this is unknown, capsule is one factor that varies between the two. 
In the opaque phase, which is prevalent in invasive disease, capsule levels are significantly higher than 
those seen in the transparent phenotype, which are favoured in the asymptomatic colonisation of the 
nasopharynx [35]. The capsule is also known to be recognized by the host immune system, via C-type 
lectin expressed by macrophages in the spleen (SIGN-R1). With the spleen playing an important role in 
pneumococcal clearance [36], it is not surprising that mice with this receptor knocked out showed 
reduced survival to infection [37]. 
Thus, these observations suggest that in all situations a thicker capsule may not be optimal, 
and that regulation will be critical. Mechanisms other than resistance to opsonophagocytosis have also 
been implicated in the importance of the capsule. For instance, the capsule has been shown to interfere 
with the association of S. pneumoniae with neutrophil extracellular traps [38], and it can increase 
tolerance to antibiotics through an inhibition of lysis [39]. Additionally, Nelson et al. [16] suggested 
that rather than being due to protection from opsonophagocytosis, the capsule was required during 
colonisation as a result of the capsule enabling the pathogen to avoid association with the luminal 
mucus in the nasopharynx. This was hypothesized to be a result of the negative charge of the majority 
of pneumococcal capsule serotypes. 
The charge of the capsule contributes to other interactions with the host as well. Human 
neutrophil defensins are cationic antimicrobial peptides that have been shown to be critical for the 
ability of neutrophils to kill the pneumococcus [40]. Beiter et al. [41] suggested that the negative 
charge of capsule makes pneumococci more susceptible to these antimicrobial peptides. Indeed, it may 
be interesting if this is the case with other antimicrobial peptides, as the majority are positively charged. 
However, this interaction may actually be beneficial for the bacteria. A recent publication has 
suggested that anionic capsular polysaccharide from S. pneumoniae, as well as K. pneumoniae and P. 
aeruginosa, can act as a decoy for cationic antimicrobial peptides, including human neutrophil α-
defensin 1 [42]. This study suggests that bacteria can secrete varying levels of capsule proteins, which 




Other bacterial pathogens 
Staphylococcus aureus is another Gram-positive pathogen for which capsule is critical. Approximately 
20% of all humans have their nasal cavities colonised by S. aureus without displaying any symptoms 
[43]. Although the bacteria can be considered normal flora in these people, it is still considered to be an 
important source in the spread and pathogenesis of more serious infection. When it becomes invasive, 
S. aureus is a major cause of skin, soft-tissue, respiratory, bone, joint, and endovascular disorders [44]. 
Bacteremia from S. aureus, particularly when leading to sepsis, can cause multi-organ dysfunction in 
severe cases. It also a common causative agent of toxic shock syndrome due to the numerous toxins it 
produces [45]. These include serotoxins, such as protein-alpha toxin, which can cause proinflammatory 
changes in mammalian cells by pore-formation. Additionally, S. aureus produces a host of enterotoxins, 
all part of a family of staphylococcal and streptococcal pyrogenic exotoxins. These are all powerful 
superantigens, in that they stimulate non-specific proliferation of T-cells [46]. While being one of the 
first bacteria to be treated with penicillin in the 1940’s, antibiotic resistance was a clinical reality 
within the same decade. Today, methicillin-resistant S. aureus (MRSA) in particular is a global health 
concern [43,47,48]. Although more clonal complexes are known, 88% of all S. aureus that are isolated 
can be assigned to one of 11 previously known serotypes. Serotyping studies have shown that the 
majority of clinical isolates possess type 5 or type 8 capsules. Indeed, in recent studies in the United 
States and the Netherlands 92% and 82% of isolates were either type 5 or type 8 respectively [49,50]. 
As for pneumococcus, a capsule produced by a Wzy-dependent system is a critical factor [51,52]. It 
plays an important role in virulence, with unencapsulated mutants showing defects in animal models 
[53], while vaccination with capsule has also been shown to be protective [54]. An additional study, 
searching for S. aureus virulence genes using mariner-based mutagenesis, identified a number of genes 
likely involved in capsule synthesis to be important for virulence [55]. As with S. pneumoniae, the 
capsule likely acts as a protective barrier and helps the bacteria resist against opsonophagocytic uptake 
and death [53].  
The discovery of new targets for virulence seems even more important in Gram-negative 
pathogens, which are traditionally more difficult to treat due to the presence of the outer membrane. 
Capsule in Gram-negative pathogens are also crucial virulence determinants as has been discussed 
recently for urinary tract infections caused by E. coli [56], through similar mechanisms to Gram-
positive bacteria, via evasion of complement and inhibition of opsonophagocytosis, as well as their 
contributions to biofilm formation. In recent times, the capsule of K. pneumoniae has also shown to be 
critical, through its ability to act as an anti-phagocytic factor [57], while also promoting resistance to 
complement mediated lysis [58]. The emerging pathogen Acinebacter baumanii [59] also produces a 
polysaccharide capsule that has been implicated in its ability to cause infection. Thus, capsule of Gram-
negative bacteria, some synthesized via alternative routes not including the Wzy-dependent pathway, 
are also valid drug targets, with studies already published looking for inhibitors to disrupt E. coli Group 
2 capsule synthesis [60].  
 
 
Capsule genes and synthesis 
The capsule is comprised of a diverse array of polysaccharides on the bacterial cell surface, and the 
many chemically distinct sugar moieties available for the synthesis of polysaccharides result in high 
variability. These moieties can in turn be covalently linked by several different glycosidic bonds, 
leading to an even greater variation of both branched and unbranched polysaccharides. Three distinct 
capsular biosynthetic pathways have been identified: the Wzy-dependent, the synthase-dependent, and 
the ABC transporter-dependent pathways. The former two of these were recently reviewed by Yother 
in 2011 [9]. The ABC transporter-dependent pathway and the capsule of Gram-negative bacteria was 
recently reviewed by Cuthbertson et al. [61]. The ABC transporter-dependent pathway is not known to 
play any significant role in Gram-positive capsular biosynthesis, while the Wzy- and synthase-
dependent pathways are well described in multiple Gram-positive bacteria.  
 
 Wzy pathway 
The Wzy-dependent pathway is determined by the CPS biosynthesis (cps) locus situated between the 
dexB and aliA genes on the S. pneumoniae chromosome. The size of the locus across the > 90 serotypes 
studied varies from 10.3 to 30.3 kb with an average of 20.7 kb with flanking sequences showing 
evidence of mobile genetic elements. Despite size differences and transposable elements, the 
organisation of the cps locus is conserved across all serotypes. Starting at the 5’ end, there is a cluster 
of 4 regulatory genes; cpsA, cpsB, cpsC, and cpsD (also known as wzg, wzh, wzd, wze) discussed in 
detail below. While cpsA is well conserved, cpsB, cpsC and cpsD are divided into two groups, with one 
set associated with carriage, and the other with invasive disease [62]. These regulatory genes are in 
most cases followed by cpsE (or wchA), the initial glucose phosphate transferase, and then wzy, the 
polysaccharide polymerase from which the pathway takes its name. After the succeeding flippase gene 
(wzx), the otherwise conserved order breaks up and is considered serotype specific, with glycosyl and 
acetyl transferases, genes for nucleotide diphosphate sugar biosynthesis and modification. Interestingly, 
while the majority of the locus has a G+C content consistent with the rest of the genome, the 
polymerase and the flippase (wzy and wzx) are more A+T rich [63].  
 Although a great deal of work remains before a complete model for Wzy-dependent synthesis 
of CPS can be postulated, much is known about the process. In S. pneumoniae, CPS synthesis begins in 
the cytoplasm by transfer of a sugar phosphate to undecaprenol-phosphate (Und-P); this forms a 
monosaccharide-PP-Und, the precursor molecule for oligosaccharide repeat unit synthesis. This first 
step is catalysed by an initiating glycosyl transferase, by transferring a sugar moiety such as glucose, 
N-acetyl-D-galactosamine or N-acetyl-D-glucosamine, depending on serotype. Several more sugar 
moieties, either identical or different, get added by glycosyl transferases until an oligosaccharide-PP-
Und has been synthesised. This constitutes a repeat unit, and is subsequently flipped over by the Wzx 
flippase to the external side of the cytoplasmic membrane [64]. On this side, polysaccharides are 
extended by adding oligosaccharide-PP-Und repeat units to the reducing end of the chains. This is done 
in a non-processive manner by the Wzy polymerase and, once complete, the chain can be attached to 
an anchor. In capsule-forming Gram-positive bacteria, most polysaccharides are covalently attached to 
the cell, either to peptidoglycan or to other components in the cell membrane [9,65]. Some notable 
properties of CPS generated by the Wzy-dependent pathway is the variation in sugars making up the 
repeat units, the existence of branch points, and the degree of variation in number of repeat units 




Regulation of capsular biosynthesis in a number of both Gram-positive and Gram-negative bacteria is 
mediated via a phosphoregulatory system, consisting of bacterial-tyrosine kinases (BY-kinases), and 
their cognate phosphatases. While tyrosine kinases were long thought to be present only in eukaryotes, 
in the past decade much work has shown the importance of BY-kinases with recent reviews 
highlighting these enzymes [66,67]. In S. pneumoniae, regulation of capsule production is mediated by 
the manganese-dependent phosphotyrosine protein-phosphatase CpsB; the autophosphorylating 
protein-tyrosine kinase CpsD; and the membrane-bound CpsC (a polysaccharide co-polymerase (PCP) 
2b protein) [68]), which is required for CpsD kinase activity. These regulatory genes are all located 
towards the 5’–end of the cps locus, along with CpsA, a member of the LytR-Cps2A-Psr (LCP) protein 
family. Deletion of all four of these genes have been shown to result in the production of significantly 
less capsule, highlighting their importance in capsule regulation [15]. 
While CpsA has been proposed to act as regulatory factor with evidence that is binds to the 
promoter region of the cps locus [69], a recent study has questioned this. Eberhart et al. (2012) have 
provided evidence that CpsA is responsible for the covalent attachment of the capsule to the cell wall 
[70]. CpsA is thought likely to bind the undecaprenol-pyrophosphoryl-linked capsule precursor to 
transfer the capsule to the cell wall. Interestingly, however, mutants in cpsA are just as virulent as the 
wt in in vivo models of pneumococcal infection [15], which may be due to the presence of other LCP 
family members (LytR and Psr) which may function to attach capsule in the absence of CpsA.  
 
The remaining elements, CpsB, CpsC, and CpsD, are likely involved in a phosphoregulatory cycle, 
although the exact mechanism is still not understood. While we have seen a positive correlation 
between the phosphorylation of CpsD and capsule production, others have seen the opposite. However 
the system functions, it is clear that a cycle between phosphorylated and non-phosphorylated is 
important, not only in the pneumococcus, but  other bacterial pathogens as well (e.g. S. aureus and E. 
coli) [14,15,71].  
 
The organisation of the homologous BY-kinase differs between Gram-positive and -negative bacteria, 
although the function remains essentially identical. Both groups have an intracellular domain 
containing catalytic sequences called Walker A and B motifs, as well as an additional A’ motif 
positioned between A and B [66]. Initially, the presence of the Walker motifs made it seem likely that 
these proteins were ATPases, since Walker A and B motifs predominantly occur in the P-loop of 
ATP/GTP binding proteins. Soon after their discovery though, they were shown to autophosphorylate 
and their role as BY-kinases established [72–74]. The BY-kinase Walker motifs are different from the 
canonical sequences though [75]. Of the [G/A]X(4)GK[S/T] Walker A motif, only the GK[S/T] amino 
acids are well conserved. Meanwhile, the Walker B motif is extended to [ILVFM](3)DX(2)P, 
following the additional Walker A’ motif with sequence [ILVFM](3)DXDXR. Finally, following the 
Walker motifs, a tyrosine-rich C-terminus serves as the main site for phosphorylation, with up to 7 
phosphorylatable tyrosine residues.  
In Gram-negative bacteria, the BY-kinase is expressed as a single membrane-spanning 
polypeptide, also known as a PCP 2a protein [68], with the C-terminal kinase domain on the 
cytoplasmic side. Examples of this are Etk and Wzc in E. coli [76,77], but homologous proteins are 
also evident in other Gram-negative pathogens such as K. pneumoniae [78]. In Gram-positive bacteria, 
this protein is split into two such as in S. pneumoniae with the membrane spanning CpsC and 
cytoplasmic CpsD. The C-terminal region of CpsD contains the catalytic Walker motifs, as well as the  
phosphorylation sites of the tyrosine-rich cluster [79].  
 This is also the case in S. aureus, where the kinase consists of the membrane-bound CapA, whose 29 
most C-terminal residues tightly interact with the soluble CapB protein. The determination of the 
CapAB structure has shown that the interface between CapB and CapA describes a shallow indentation 
of ~1350 Å
2
 on the CapB surface (PISA server [80,81]). The C-terminal chain of CapA complements 
the central CapB -sheet by adding a terminal strand to it; the interaction is otherwise predominantly 
hydrophobic in nature (Figure 2). Despite this organisational difference, both E. coli BY-kinases share 
a ~30% sequence identity with the corresponding S. aureus structure along with a high degree of 
structural similarity (Table 1). There is currently no BY-kinase structure available from S. pneumoniae. 
The closest homologous protein to CpsD is CapB from S. aureus with a sequence identity of 34%. By 
using the available structures from E. coli and S. aureus for a structure-based alignment, CpsD can be 
shown to have several features in common with those BY-kinases (Figure 1). This includes three 
aspartic acid residues that are part of or located near the conserved Walker A and B motifs. These 
residues are involved in the coordination of the -phosphate of the ATP substrate, along with a 
conserved aspartic acid interacting with the ribose. All of these align perfectly in four sequences shown 
in Figure 1. While the role of CpsC in this cycle was at first less obvious, early work established its 
necessity for the proper function of CpsD [71,82,83]. Additionally, we recently showed that a number 
of defined amino acid mutations in CpsC can affect capsule polymerisation, CpsD phosphorylation and 
ligation of capsule to the cell wall [84]. A recent study showed that while not affecting the attachment 
of capsule to the cell wall, CpsC and CpsD played critical roles in the synthesis of the capsule at the 
division septum [85]. This did not seem to require phosphorylation of CpsD, as the C-terminal cluster 
of tyrosines was not required. Thus, this has led to the suggestion that there may be more than one 
method for controlling regulation of capsule in the pneumococcus – septal and non-septal. 
 The structures of bacterial protein tyrosine phosphatases were solved from both Gram-positive 
and Gram–negative organisms; CpsB from S. pneumoniae, and Wzb from E. coli [86]. These proteins 
share neither any significant sequence identity nor any structural similarity (Table 1). The structure of 
CpsB showed that it is a member of the polymerase and histidinol phosphatase (PHP) domain family of 
protein folds, as had been suggested by an earlier study via sequence comparisons [87]. On the other 
hand Wzb is associated with the low molecular weight phosphotyrosine protein phosphatases family 
[88]. The catalytic mechanism of Wzb could be inferred from previously studied phosphatases, but 
CpsB presented a novel metal-dependent mode of action. As a phosphatase, CpsB is not specific for its 
cognate autokinase CpsD, but has shown in vitro activity towards Wzc as well [86]. Thus, this would 
suggest that while these two phosphatases are relatively divergent, they share some similarity in their 
active sites. Recently, the structure of YwqE, a phosphatase from the Gram-positive bacterium Bacillus 
subtilis was solved [89]. 
While it is beyond doubt that CpsB is a major component in regulating CPS, the specific 
effects on the Wzy-dependent pathway has proven hard to conclusively show. We have shown in a 
variety of strains that defined mutations in CpsB lead to a reduction in capsule [15,71,90], while 
Bender et al. [91] saw a slight increase in the S. pneumoniae strain D39. This has led to confusion as to 
whether phosphorylation of CpsD is associated with a positive or negative effect on capsule expression. 
In Gram-negative bacteria, evidence has suggested that phosphorylation is essential. In E. coli K-12 
and K30, deletion of the gene encoding the protein tyrosine phosphatase Wzb results in no synthesis of 
colanic acid [1] (an exopolysaccharide produced by all E. coli isolates under stress conditions) and CPS 
[12]. In other words, this PTP is thought to be essential for CPS synthesis in Gram-negative bacteria. 
Whichever the case, CpsB and other bacterial tyrosine phosphatases are tightly bound to the regulation 
of CPS. Furthermore, defined mutations in CpsB have been shown to produce profound defects in a 
number of in vivo animal models [14,15], showing the importance of this protein tyrosine phosphatase 
to the pathogenicity of this organism. 
Capsule has also been shown to be regulated by other mechanisms in S. pneumoniae. This 
includes the so far undefined phase variation [35], with some suggestion that part of this selection for 
phenotype may be caused by levels of oxygen. Indeed, CpsD phosphorylation levels vary in multiple 
strains with oxygen levels [92], while the specific activity of both CpsC and CpsB are affected by 
oxygen availability [9]. The catabolite control protein A (CcpA; also known as RegM), was previously 
shown to affect regulation of the cps regulon and to have an effect on the level of capsule in S. 
pneumoniae [93], while a recent study has suggested that this important regulator plays a role in the 
attachment of capsule to the cell wall at least in certain circumstances [94]. While this factor is 




Scope for drug design 
The Wzy-dependent pathway involves several key events which could potentially be targeted by 
rational drug design. The phosphoregulatory system in particular seems to be well suited for this, given 
the many studies that have shown its central role in CPS production, and its presence across a wide 
range of bacterial pathogens [72–74,95]. Of the two processes, phosphorylation and dephosphorylation, 
the effects of BY-kinases are the better studied and have been the focus of recent reviews [66,77]. The 
success of the last decade in targeting human kinases has made bacterial kinases tractable as drug 
targets as well. Although most work so far has been focused on bacterial histidine kinases [96], recent 
developments in the study of BY-kinases may generate more interest in them as drug targets. There are 
BY-kinase crystal structures from both Gram-positive and Gram–negative organisms available. The 
structures from E. coli and S. aureus are very similar; the proteins all share sequence identities ≥ 30% 
(Table 1). At the same time, these potential drug targets have very little in common with any known 
structure or protein sequence found in humans. This is a necessary, rather than sufficient, attribute in a 
drug target to minimize the potential drug from having adverse effects on human pathways. This 
marked difference from eukaryotic proteins is backed up by experimental evidence. BY-kinases have 
been shown to be insensitive to compounds known to have an effect on human kinases, and are unable 
to modify substrates easily phosphorylated by eukaryotic enzymes [97,98]. High resolution is 
advantageous for structure-based drug design approaches, and the highest resolution available crystal 
structure of a BY kinase is the S. aureus CapAB at 1.8 Å resolution [82]. The obvious site to focus on, 
the ATP-binding pocket, may not alone provide a sufficiently specific target. The nucleotide-binding 
side of this pocket, however, is located in close proximity to the binding groove occupied by the C-
terminal end of the interacting CapA (CapA-Ct; Figure 2). It is conceivable that a drug lead could 
garner enough specificity by interacting with features from both these sites on the CapB surface. Given 
the near-linear stretch of CapA-Ct leading up to the binding pocket, this could potentially be 
approached by using peptide-inhibitors as a lead towards peptidomimetic drugs. This is potentially the 
case in CpsC-Ct/CpsD as well; the majority of residues in the linear part of the CpsD binding groove 
are conserved between S. pneumoniae and S. aureus (Figure 1). The CapA-Ct/CapB interface is 
otherwise shallow and predominantly hydrophobic in nature, with few pockets that could potentially be 
exploited. Another feature of potential interest is the fact that BY-kinases have been shown to form 
large oligomeric complexes. In the S. aureus CapAB K55M mutant, a circular octamer is observed in 
the crystal structure, formed via two ~1000 Å
2
 interfaces on each monomer. This interface, consisting 
mainly of four charged amino acid residues, also involves the tyrosine-rich C-terminal of one protomer 
interacting with the active site of the neighbouring chain. It is not known how well these findings 
reflect the in vivo situation. Although not observed in solution, it is conceivable that the octameric state 
is still present in vivo when stabilized by the transmembrane domain of the full length CapAB complex. 
Mutating these charged interface residues, all highly conserved in many BY-kinases (except S. 
pneumoniae), has no significant effect on the autokinase activity of the proteins [82]. However, since 
these were mutations to alanine residues, they would not be a sterical hinder for the transient 
interactions required for autophosphorylation. It seems feasible that this activity could be inhibited by 
disrupting the required protein-protein interaction. Although targeting active site cavities have a much 
longer history in drug design, and targeting protein interfaces presents its own set of challenges, the use 
of small molecules as drug leads by inhibiting protein-protein interactions have met with some recent 
success [99,100].  
 The S. pneumoniae protein tyrosine phosphatase CpsB shares very low sequence identity to 
any human proteins, with a putative deoxribonuclease TATP-domain protein as the most closely 
related structure. Although similar in overall structure, both belong to the TIM-barrel class of folds, 
their respective active sites are dissimilar enough that a prospective inhibitor could likely be made 
specific for the bacterial enzyme. On the other hand, the E. coli counterpart Wzb is clearly related in 
structure to human low molecular weight phosphatases, with sequence identities at ~30%. These are 
very similar in overall structure, and nearly identical in their phosphate-binding site, which renders 
some doubt over whether Wzb will be a useful drug target, while CpsB is more attractive. Of the 
bacterial phosphatases for which there is a structure, only YwqE from B. subtilis is utterly unlike any 
human structure or sequence to date. Likewise S. aureus phosphatases, for which there is currently no 
crystal structure, have little sequence identity with human proteins and could be considered a viable 
target on that basis (Figure 3). Although targeting phosphatases is a more recent development than 
using kinases as drug targets, dozens of new PTP inhibitors are reported annually [101]. These are 
mainly developed for the treatment of non-pathogenic diseases such as diabetes mellitus, cancer, and 
neural disorders. As potential drugs against pathogens, there has been some success in targeting PTPs 
in both Gram-positive and –negative organisms, for example Mycobacterium tuberculosis [102–104] 
and Yersinia pestis [105,106]. Although demonstrably viable as drug targets, and increasingly specific 
compounds are under development, there are as of yet no clinically approved PTP inhibitors available. 
 
Conclusions 
Given the importance of proteins associated with the bacterial capsule as virulence factors, 
compromising the capsule synthesis during infections should sway the balance towards the innate 
immune defence of the host and allow control of bacterial numbers. This strategy would not directly 
lead to bacterial cell death, and as such inflammatory cell wall products should not be released into the 
hosts circulation on a large scale, and resistance selection pressure should also be reduced as the drug 
targets are not essential for bacterial viability and growth. In reality, this concept can only be 
investigated by using novel modulators that are currently being identified and developed (Add 
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Structure-based sequence alignment of BY-kinases from S. aureus, S. pneumoniae, and two from E. 
coli. Of the four, structures are available for all but S. pneumoniae and used for structure-based 
alignment. The split between the C-terminus of CapA and the N-terminus of CapB is indicated above 
the alignment, and the split between CpsC and CpsD is indicated below the alignment. CapB catalytic 
residues K55, S56, D77, D79, and D157 are labelled with "*". CapB residues directly interacting with 
the CapA linear C-terminus are labelled with "#". Sequence numbering is according to Uniprot records. 
Aligned by the T-Coffee (Expresso) web service [107]. 
 
Figure 2 
Structure of the CapAB monomer. Non-carbon atom are in CPK colours. A) Ribbon representation of 
the overall structure; CapA C-terminus in grey, CapB in rainbow colouring from blue N-terminus to 
red C-terminus. Stick representation of ADP bound to the active site. B) Surface representation of the 
CapB binding groove interacting with the linear C-terminal stretch of CapA in pink. CapB surface 
collared by electrostatic potential from -0.5 V in red to 0.5 V in blue. CapA residues suffixed fixed by 
lower case ‘a’, CapB by lower case ‘b’. Interactions that a putative inhibitor could make use of include 
the hydrophobic pocket filled by L215a, and the pi stacking interaction between F221a and the 
nucleotide moiety of ADP. Figures produced using CCP4mg [108]. 
 
Figure 3 
Structure-based sequence alignment of protein tyrosine phosphatases from S. pneumoniae, B. subtilis, 
and S. aureus. Of the three, structures are available for all but S. aureus and used for structure-based 
alignment. The CpsB residue R139, identified as the key residue for its catalytic activity, is labelled by 
double "*". CpsB residues interacting with the manganese cluster are labelled with single "*". 





PTKs     Protein  
Protein Organism PDB Ref CapAB Wzc Etk 
CapAB S. aureus 3bfv [82] 1.8Å 31% seq id 29% seq id 
Wzc E. coli 3la6 [77] Z: 15.2 2.5Å 57% seq id 
Etk E. coli 3cio [76] Z: 15.7 Z: 17.3 3.2Å 
       
PTPs     Protein  
Protein Organism PDB Ref CpsB Wzb YwqE 
CpsB S. pneumoniae  2wjd [86] 2.8Å 13% seq id 30% seq id 
Wzb E. coli  2wja [86] Z: 3.6 2.5Å 5% seq id 
YwqE B. subtilis  3qy6 [89] Z: 12.8 Z: 3.4 1.8Å 
 
Table 1 - text 
Structures of representative phosphoregulatory proteins PTKs: protein tyrosine kinases; PTPs: protein 
tyrosine phosphatases; Å: highest resolution of structure. Z: Z-score; measures the statistical 
significance of a match in terms of Gaussian statistics. The higher Z-score, the higher the statistical 
significance of the match is. % seq id: fraction of pairs of identical residues in alignment. Data from 
PDBe-fold [109,110]. 
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